Literature DB >> 27480574

Inflammation Effects on Motivation and Motor Activity: Role of Dopamine.

Jennifer C Felger1,2, Michael T Treadway1,2,3.   

Abstract

Motivational and motor deficits are common in patients with depression and other psychiatric disorders, and are related to symptoms of anhedonia and motor retardation. These deficits in motivation and motor function are associated with alterations in corticostriatal neurocircuitry, which may reflect abnormalities in mesolimbic and mesostriatal dopamine (DA). One pathophysiologic pathway that may drive changes in DAergic corticostriatal circuitry is inflammation. Biomarkers of inflammation such as inflammatory cytokines and acute-phase proteins are reliably elevated in a significant proportion of psychiatric patients. A variety of inflammatory stimuli have been found to preferentially target basal ganglia function to lead to impaired motivation and motor activity. Findings have included inflammation-associated reductions in ventral striatal neural responses to reward anticipation, decreased DA and DA metabolites in cerebrospinal fluid, and decreased availability, and release of striatal DA, all of which correlated with symptoms of reduced motivation and/or motor retardation. Importantly, inflammation-associated symptoms are often difficult to treat, and evidence suggests that inflammation may decrease DA synthesis and availability, thus circumventing the efficacy of standard pharmacotherapies. This review will highlight the impact of administration of inflammatory stimuli on the brain in relation to motivation and motor function. Recent data demonstrating similar relationships between increased inflammation and altered DAergic corticostriatal circuitry and behavior in patients with major depressive disorder will also be presented. Finally, we will discuss the mechanisms by which inflammation affects DA neurotransmission and relevance to novel therapeutic strategies to treat reduced motivation and motor symptoms in patients with high inflammation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27480574      PMCID: PMC5143486          DOI: 10.1038/npp.2016.143

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  413 in total

1.  Oscillations in the basal ganglia.

Authors:  T Wichmann; M R DeLong
Journal:  Nature       Date:  1999-08-12       Impact factor: 49.962

2.  Erratum: GTP-cyclohydrolase deficiency responsive to sapropterin and 5-HTP supplementation: relief of treatment-refractory depression and suicidal behaviour.

Authors:  Lisa Pan; Brian William McKain; Suneeta Madan-Khetarpal; Marianne McGuire; Rasim S Diler; James M Perel; Jerry Vockley; David A Brent
Journal:  BMJ Case Rep       Date:  2011-06-30

3.  Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides.

Authors:  Susana G Torres-Platas; Cristiana Cruceanu; Gary Gang Chen; Gustavo Turecki; Naguib Mechawar
Journal:  Brain Behav Immun       Date:  2014-05-20       Impact factor: 7.217

4.  Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder.

Authors:  Antonio Drago; Concetta Crisafulli; Marco Calabrò; Alessandro Serretti
Journal:  J Affect Disord       Date:  2015-03-26       Impact factor: 4.839

5.  Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression.

Authors:  George I Papakostas; Timothy Petersen; David Mischoulon; Julie L Ryan; Andrew A Nierenberg; Teodoro Bottiglieri; Jerrold F Rosenbaum; Jonathan E Alpert; Maurizio Fava
Journal:  J Clin Psychiatry       Date:  2004-08       Impact factor: 4.384

6.  Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity.

Authors:  Daniel Lindqvist; Shorena Janelidze; Peter Hagell; Sophie Erhardt; Martin Samuelsson; Lennart Minthon; Oskar Hansson; Maria Björkqvist; Lil Träskman-Bendz; Lena Brundin
Journal:  Biol Psychiatry       Date:  2009-03-06       Impact factor: 13.382

7.  A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.

Authors:  Cristina Cusin; Nadia Iovieno; Dan V Iosifescu; Andrew A Nierenberg; Maurizio Fava; A John Rush; Roy H Perlis
Journal:  J Clin Psychiatry       Date:  2013-07       Impact factor: 4.384

8.  Markers of inflammation and stress distinguish subsets of individuals with schizophrenia and bipolar disorder.

Authors:  S G Fillman; D Sinclair; S J Fung; M J Webster; C Shannon Weickert
Journal:  Transl Psychiatry       Date:  2014-02-25       Impact factor: 6.222

9.  Levodopa reverses cytokine-induced reductions in striatal dopamine release.

Authors:  Jennifer C Felger; Carla R Hernandez; Andrew H Miller
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-31       Impact factor: 5.176

Review 10.  The role of immune genes in the association between depression and inflammation: a review of recent clinical studies.

Authors:  Chiara Bufalino; Nilay Hepgul; Eugenio Aguglia; Carmine M Pariante
Journal:  Brain Behav Immun       Date:  2012-05-08       Impact factor: 7.217

View more
  110 in total

1.  Pilot investigation into the sickness response to influenza vaccination in adults: Effect of depression and anxiety.

Authors:  Jessica A Harper; Charles South; Madhukar H Trivedi; Marisa S Toups
Journal:  Gen Hosp Psychiatry       Date:  2017-07-25       Impact factor: 3.238

Review 2.  The Bidirectional Relationship of Depression and Inflammation: Double Trouble.

Authors:  Eléonore Beurel; Marisa Toups; Charles B Nemeroff
Journal:  Neuron       Date:  2020-06-17       Impact factor: 17.173

3.  Inflammation-induced motivational changes: Perspective gained by evaluating positive and negative valence systems.

Authors:  Elisabeth G Vichaya; Robert Dantzer
Journal:  Curr Opin Behav Sci       Date:  2018-02-10

4.  The Immunology of Behavior-Exploring the Role of the Immune System in Brain Health and Illness.

Authors:  Andrew H Miller; Ebrahim Haroon; Jennifer C Felger
Journal:  Neuropsychopharmacology       Date:  2017-01       Impact factor: 7.853

5.  Inflammation and dimensions of reward processing following exposure to the influenza vaccine.

Authors:  Chloe C Boyle; Kate R Kuhlman; Larissa N Dooley; Marcie D Haydon; Theodore F Robles; Yuen-Siang Ang; Diego A Pizzagalli; Julienne E Bower
Journal:  Psychoneuroendocrinology       Date:  2018-11-20       Impact factor: 4.905

6.  Association Between Interleukin-6 and Striatal Prediction-Error Signals Following Acute Stress in Healthy Female Participants.

Authors:  Michael T Treadway; Roee Admon; Amanda R Arulpragasam; Malavika Mehta; Samuel Douglas; Gordana Vitaliano; David P Olson; Jessica A Cooper; Diego A Pizzagalli
Journal:  Biol Psychiatry       Date:  2017-03-28       Impact factor: 13.382

Review 7.  Corticolimbic circuitry in the modulation of chronic pain and substance abuse.

Authors:  Anna M W Taylor
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-05-10       Impact factor: 5.067

Review 8.  Can't or Won't? Immunometabolic Constraints on Dopaminergic Drive.

Authors:  Michael T Treadway; Jessica A Cooper; Andrew H Miller
Journal:  Trends Cogn Sci       Date:  2019-04-02       Impact factor: 20.229

9.  Higher Peripheral Inflammatory Signaling Associated With Lower Resting-State Functional Brain Connectivity in Emotion Regulation and Central Executive Networks.

Authors:  Robin Nusslock; Gene H Brody; Casey C Armstrong; Ann L Carroll; Lawrence H Sweet; Tianyi Yu; Allen W Barton; Emily S Hallowell; Edith Chen; James P Higgins; Todd B Parrish; Lei Wang; Gregory E Miller
Journal:  Biol Psychiatry       Date:  2019-05-01       Impact factor: 13.382

10.  An Association Between the Inflammatory Biomarker GlycA and Depressive Symptom Severity.

Authors:  Samara Huckvale; Stephanie Reyes; Alexandra Kulikova; Anand Rohatgi; Kayla A Riggs; E Sherwood Brown
Journal:  J Clin Psychiatry       Date:  2020-11-17       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.